Victor Tapson
- Imatinib in pulmonary arterial hypertension, a randomized, efficacy study (IMPRES)By Marius Hoeper, Robyn J. Barst, Nazzareno Galié, Paul Hassoun, Nick Morrell, Andrew Peacock, Gérald Simonneau, Victor Tapson, Fernando Torres, Keith Lu, Debbie Quinn and Ardeschir GhofraniMarius Hoeper1Respiratory Medicine, Medizinische Hochschule, Hannover, GermanyRobyn J. Barst2Respiratory Medicine, Columbia University, New York, NY, United StatesNazzareno Galié3Respiratory Medicine, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItalyPaul Hassoun4Respiratory Medicine, Johns Hopkins University, Baltimore, MD, United StatesNick Morrell5Respiratory Medicine, Addenbrookes and Papworth Hospitals, Cambridge, United KingdomAndrew Peacock6Respiratory Medicine, Golden Jubilee National Hospital, Glasgow, United KingdomGérald Simonneau7Respiratory Medicine, Université Paris-Sud XI, Orsay, FranceVictor Tapson8Respiratory Medicine, Duke University Medical Center, Durham, NC, United StatesFernando Torres9Respiratory Medicine, UT Southwestern Medical Center, Dallas, TX, United StatesKeith Lu10Respiratory Medicine, Novartis Pharmaceuticals, East Hanover, NJ, United StatesDebbie Quinn11Respiratory Medicine, Novartis Pharmaceuticals, Cambridge, MA, United StatesArdeschir Ghofrani12Respiratory Medicine, University Hospital Giessen and Marburg GmbH, Giessen, Germany
- Long-term safety and efficacy of imatinib in pulmonary arterial hypertensionBy Marius Hoeper, Robyn Barst, Nazzareno Galie, Paul Hassoun, Nicholas Morrell, Andrew Peacock, Gérald Simonneau, Victor Tapson, Fernando Torres, David Lawrence, Deborah Quinn and Hossein Ardeschir GhofraniMarius Hoeper1Respiratory Medicine, Medizinische Hochschule, Hannover, GermanyRobyn Barst2Respiratory Medicine, Columbia University, New York, NY, United StatesNazzareno Galie3Respiratory Medicine, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItalyPaul Hassoun4Respiratory Medicine, Johns Hopkins University, Baltimore, MD, United StatesNicholas Morrell5Respiratory Medicine, Addenbrookes and Papworth Hospitals, Cambridge, United KingdomAndrew Peacock6Respiratory Medicine, Golden Jubilee National Hospital, Glasgow, United KingdomGérald Simonneau7Respiratory Medicine, Université Paris-Sud XI, Orsay, FranceVictor Tapson8Respiratory Medicine, Duke University Medical Center, Durham, NC, United StatesFernando Torres9Respiratory Medicine, UT Southwestern Medical Center, Dallas, TX, United StatesDavid Lawrence10Respiratory Medicine, Novartis Horsham Research Centre, Horsham, West Sussex, United KingdomDeborah Quinn11Respiratory Medicine, Novartis Pharmaceuticals, Cambridge, MA, United StatesHossein Ardeschir Ghofrani12Respiratory Medicine, University Hospital Giessen and Marburg GmbH, Giessen, Germany
- Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study resultsBy Olivier Sitbon, Richard Channick, Kelly Chin, Aline Frey, Nazzareno Galiè, Hossein-Ardeschir Ghofrani, Marius M. Hoeper, Irene Lang, Franck-Olivier Le Brun, Vallerie McLaughlin, Ralph Preiss, Lewis J. Rubin, Gérald Simonneau, Victor Tapson and Sean GaineOlivier Sitbon1Hôpital Universitaire de Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, Paris, FranceRichard Channick2Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA United StatesKelly Chin3Pulmonary Hypertension Program, UT Southwestern Medical Center, Dallas, United StatesAline Frey4Clinical Research, Actelion Pharmaceuticals Ltd, Allschwil, SwitzerlandNazzareno Galiè5Istituto di Malattie dell'Apparato Cardiovascolare, University of Bologna, Bologna, ItalyHossein-Ardeschir Ghofrani6UGMLC, University of Giessen and Marburg Lung Center, Giessen, GermanyMarius M. Hoeper7Department of Respiratory Medicine, Hannover Medical School and German Center of Lung Research, Hannover, GermanyIrene Lang8Dept of Internal Medicine II, Division of Cardiology, AKH, Medical University of Vienna, Vienna, AustriaFranck-Olivier Le Brun4Clinical Research, Actelion Pharmaceuticals Ltd, Allschwil, SwitzerlandVallerie McLaughlin9Division of Cardiovascular Medicine, University of Michigan Health System, Ann Arbor, United StatesRalph Preiss4Clinical Research, Actelion Pharmaceuticals Ltd, Allschwil, SwitzerlandLewis J. Rubin10Division of Pulmonary and Critical Care Medicine, University of California, San Diego, United StatesGérald Simonneau1Hôpital Universitaire de Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, Paris, FranceVictor Tapson11Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United StatesSean Gaine12National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.